Compositions for regenerating defective or absent myocardium
First Claim
Patent Images
1. An injectable graft composition for myocardial tissue regeneration, said composition comprising an acellular extracellular matrix (ECM) from a mammalian tissue source comprising stomach submucosa, said ECM comprising endogenous transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG) protein, said GAG protein comprising at least 0.1% by weight of said composition, said GAG protein being linked to said ECM, wherein said GAG protein stimulates angiogenic effects of FGF-2 and interacts with TGF-β
to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.
3 Assignments
0 Petitions
Accused Products
Abstract
Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
-
Citations
1 Claim
-
1. An injectable graft composition for myocardial tissue regeneration, said composition comprising an acellular extracellular matrix (ECM) from a mammalian tissue source comprising stomach submucosa, said ECM comprising endogenous transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG) protein, said GAG protein comprising at least 0.1% by weight of said composition, said GAG protein being linked to said ECM, wherein said GAG protein stimulates angiogenic effects of FGF-2 and interacts with TGF-β
to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added glycosaminoglycan (GAG) protein, said GAG protein comprising at least 0.1% by weight of said composition, said GAG protein being linked to said ECM, wherein said GAG protein stimulates angiogenic effects of FGF-2 and interacts with TGF-β
Specification